ACC 2015: Amgen, Regeneron/Sanofi make case for PCSK9 inhibitor safety
This article was originally published in Scrip
Executive Summary
Amgen and its competitor Regeneron Pharmaceuticals with partner Sanofi won't report data from large-scale cardiovascular outcomes studies for their PCSK9 inhibitors until 2017, but the companies are sharing longer-term data from smaller clinical trials for their cholesterol-lowering therapies in hopes of encouraging prescriptions of the injectable drugs following US FDA approval later this year.